drugset
drugset / Trial / NCT07505199

Safety and Efficacy of FAP iCDC in Ischemic Cardiomyopathy

NCT07505199 ↗

Phase 1 Recruiting 30 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety and efficacy of fibroblast activation protein (FAP)-targeted autologous immunosuppressive chimeric antigen receptor dendritic cell (iCDC) therapy in patients with ischemic cardiomyopathy, and to explore its potential as a novel therapeutic strategy for this disease.

Timeline

Start
2026-05-21
Primary completion
2028-04-01
Completion
2029-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject FAP-targeted immunosuppressive CAR-DCs Cell therapy 100000 cells/kg Intravenous
Subject FAP-targeted immunosuppressive CAR-DCs Cell therapy 400000 cells/kg Intravenous
Subject FAP-targeted immunosuppressive CAR-DCs Cell therapy 800000 cells/kg Intravenous

Indications

cardiomyopathy